TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: PF-06372865 in Subjects With Photosensitive Epilepsy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* A diagnosis and history of photoparoxysmal response on electroencephalogram (EEG) with or without a diagnosis of epilepsy for which subjects are taking up to 0 - 2 concomitant antiepileptic drugs.~* Subjects currently taking antiepileptic drug(s) to be on a stable dose for 4 weeks prior to Screening Visit.~* A minimum average standardized photosensitive range (SPR) across all screening timepoints of 4 in the most sensitive eye condition and a non-zero average in at least one other eye condition.~Exclusion Criteria:~* Subjects with a history of status epilepticus.~* Subjects who have experienced a generalized tonic-clonic convulsion in the past 6 months, at the time of the initial screening visit.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- PF-06372865 dose level 1 (Type: EXPERIMENTAL): 17.5 milligram (mg) single dose
- PF-06372865 dose level 2 (Type: EXPERIMENTAL): 52.5 mg single dose
- Placebo (Type: PLACEBO_COMPARATOR): Single dose
- Lorazepam (Type: ACTIVE_COMPARATOR): 2mg single dose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Influence of Silicone Oil on Nerve Fiber Layer Thickness After Pars Plana Vitrectomy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~- patients with rhegmatogenous retinal detachment~Exclusion Criteria:~* preexistent glaucoma~* previous retinal surgery~* placement of scleral buckle during surgery~* patients with more than 1/2 of emulsified silicone oil in anterior chamber postoperatively~* patients who develop silicone oil keratopathy postoperatively~* patients who develop silicone oil cataract which blocks visualization of posterior segment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- NO IOP (Type: None): Patients without raised IOP
- RAISED IOP (Type: None): Patients with raised IOP

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Efficacy and Safety of BIVV009 (Sutimlimab) in Participants With Primary Cold Agglutinin Disease Who Have a Recent History of Blood Transfusion (Cardinal Study)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Body weight of \>= 39 kg at screening.~* Confirmed diagnosis of primary CAD based on the following criteria: a) Chronic hemolysis; b) Polyspecific direct antiglobulin test (DAT) positive; c) Monospecific DAT strongly positive for C3d; d) Cold agglutinin titer \>= 64 at 4 degree celsius; e) Immunoglobulin G (IgG) DAT less than or equal to (\<=) 1+, and f) No overt malignant disease.~* History of at least one documented blood transfusion within 6 months of enrollment.~* Hemoglobin level \<= 10.0 g/dL.~* Bilirubin level above the normal reference range, including participants with Gilbert's Syndrome.~Exclusion Criteria:~* Cold agglutinin syndrome secondary to infection, rheumatologic disease, or active hematologic malignancy.~* Clinically relevant infection of any kind within the month preceding enrollment (e.g., active hepatitis C, pneumonia).~* Clinical diagnosis of systemic lupus erythematosus; or other autoimmune disorders with anti-nuclear antibodies at Screening. Anti-nuclear antibodies of long-standing duration without associated clinical symptoms adjudicated on a case-by-case basis during the Confirmatory Review of Patient Eligibility.~* Positive hepatitis panel (including hepatitis B surface antigen and/or hepatitis C virus antibody) prior to or at Screening.~* Positive human immunodeficiency virus (HIV) antibody at screening.~* Treatment with rituximab monotherapy within 3 months or rituximab combination therapies (e.g., with bendamustine, fludarabine, ibrutinib, or cytotoxic drugs) within 6 months prior to enrollment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BIVV009 (Type: EXPERIMENTAL): Participants with primary CAD who had a recent history of transfusion (defined as at least 1 transfusion during the last 6 months prior to screening) received an intravenous (IV) infusion of BIVV009 6.5 grams (g) (if body weight was less than \[\<\] 75 kilograms \[kg\]) or BIVV009 7.5 g (if body weight was greater than or equal to \[\>=\] 75 kg) on Day 0 and Day 7 and every 14 days thereafter in Part A up to Week 25. Participants who completed Part A per protocol through the end of treatment visit (Week 26) could continue to receive BIVV009 in Part B, every 2 weeks starting at Week 27 for up to an additional 149 weeks. All participants who completed Part A elected to continue in Part B.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Gemcitabine and Carboplatin for Elderly Patient With Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of histologically confirmed stage IIIB or IV non-small cell lung cancer~* Good performance status (ECOG 0-1)~* No previous treatment~* Age 76 years and older~* Adequate bone marrow, liver and renal functions~* No pregnant~* Measurable disease, defined as at least one lesion whose longest diameter can be accurately measured as \>=1.0 cm by spiral CT scan~* Provided written informed consent~Exclusion Criteria:~* Severe complications or a concomitant malignancy~* Prior and other concurrent radiotherapy, chemotherapy, immunotherapy, EGFR tyrosine kinase inhibitors~* Interstitial pneumonia or lung fibrosis~* Contraindicated gemcitabine or carboplatin~* Inappropriate patients for entry to this study, judged by the physicians

- Gender: ALL
- Minimum Age: 76 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Gemcitabine 1000mg/m2 Day 1,15~Carboplatin AUC=3 Day 1, 15 every 4 weeks
- 2 (Type: ACTIVE_COMPARATOR): Gemcitabine 1000mg/m2 Day 1, 8, 15

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Long Term Albumin 20% Administration in Patients With Cirrhosis and Ascites.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age above 18 years and less than 80 years.~* Diagnosis of liver cirrhosis by biopsy or by clinical, laboratory, or ultrasound.~* Daily requirement of diuretics at least 200mg of spironolactone or 100mg of spironolactone and 40 mg of furosemide~* Renal dysfunction defined by a plasma concentration of serum creatinine ≥ 1.2 mg / dl, blood urea nitrogen ≥ 25 mg / dl or a serum sodium concentration ≤ 130 mEq / L.~Exclusion Criteria:~* Refractory Ascites (paracentesis requirements over 1 month.~* Neoplastic disease including liver cancer if it exceeds the Milan criteria (one nodule\> 5 cm or three nodules\> 3 cm).~* History of transjugular intrahepatic portosystemic shunt (TIPS) or surgical shunt~* Gastrointestinal bleeding or bacterial infection documented in the past 15 days.~* Heart failure or structural heart disease.~* Organic renal insufficiency(proteinuria, hematuria and / or ultrasound data nephropathy).~* Moderate or severe lung chronic disease.~* Transplant.~* Infection with human immunodeficiency virus.~* Active addiction to drugs.~* Mental state that prevents the patient understand the nature, extent and consequences of the study, except for hepatic encephalopathy.~* Pregnancy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Albumin (Type: EXPERIMENTAL): The subjects will be receiving albumin 20% infusions

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Vitamin D Supplementation in Subjects With New Onset of Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* males or females \> 6 years~* new onset of type 1 diabetes (3 months)~Exclusion Criteria:~* pregnancy~* hypercalcemia (\>2,65 mmol/L)~* chronic disease including a long-term medication over 4 weeks per year (except type 1 diabetes)

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): peanut oil
- Vitamin D (Oleovit®) (Type: ACTIVE_COMPARATOR): cholecalciferol

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Cariprazine in the Prevention of Relapse of Symptoms in Participants With Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Participants who have provided informed consent prior to any study specific procedures.~* Participants currently meeting the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition - Text Revision (DSM-IV-TR) criteria for schizophrenia.~* Participants with normal physical examination, laboratory, vital signs, and/or electrocardiogram (ECG).~* Diagnosis of schizophrenia for a minimum of 1 year before Visit 1 (Screening).~* Positive and Negative Syndrome Scale (PANSS) total score ≥ to 70 and ≤ 120 at Visit 1 (Screening) and Visit 2 (beginning of Run-in Phase).~* Negative serum B-human chorionic gonadotropin (B-hCG) pregnancy test (applies to female participants of childbearing potential only).~* Body mass index between 18 and 40 kg/m\^2, inclusive.~Exclusion Criteria:~* Participants currently meeting DSM-IV-TR criteria for schizoaffective disorder, schizophreniform disorder, bipolar I and II and known or suspected borderline or antisocial personality disorder. or other DSM-IV-TR axis II disorders.~* Participants in their first episode of psychosis.~* Treatment-resistant schizophrenia over the last 2 years.~* Positive result from the blood alcohol test or from the urine drug screen for any prohibited medication.~* At imminent risk of injuring self or others or causing significant damage to property.~* Suicide risk.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Cariprazine - Open-label Phase (Type: EXPERIMENTAL): Participants received 3, 6, or 9 mg cariprazine orally once a day for 6 weeks; the dose could be modified during this time. The cariprazine dose was fixed at 3, 6, or 9 mg for the last 14 weeks of this 20 week Open-label Phase.
- Placebo - Double-blind Treatment Phase (Type: EXPERIMENTAL): Participants received placebo orally once a day for 26 to 72 weeks.
- Cariprazine - Double-blind Treatment Phase (Type: EXPERIMENTAL): Participants received 3, 6, or 9 mg cariprazine orally once a day for 26 to 72 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Philips Respironics BiPAP autoSV Devices in Subjects With Sleep Disorders

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 21-80~* Ability to provide consent~* Documentation of medical stability by investigator~* Subjects who currently have been on Positive Airway Pressure (PAP) therapy for ≥ 4 weeks and who previously had a Continuous Positive Airway Pressure (CPAP) titration with CAI ≥ 5.~OR Subjects who currently have been on PAP therapy for ≥ 4 weeks and who had a diagnostic study done, with a CAI ≥ 5, and were prescribed PAP therapy without a CPAP titration.~* Agreement to undergo a full-night, in-lab research CPAP Titration~* Agreement to undergo two full-night, in-lab therapy research Polysomnography (PSG) on BiPAP autoSV devices~Exclusion Criteria:~* Major medical or psychiatric condition that would interfere with the demands of the study, adherence to positive airway pressure, or the ability to complete the study. For example, unstable congestive heart failure, chronic lung disease, neuromuscular disease, daytime hypercapnia, cancer, or renal failure.~* Systolic blood pressure \< 80 mm Hg at Baseline Visit.~* Participants in whom PAP therapy is otherwise medically contraindicated.~* Participants who are unwilling to wear CPAP~* Currently prescribed oxygen therapy (as needed, nocturnal, or continuous~* Participants with previously diagnosed respiratory failure or respiratory insufficiency and who are known to have chronically elevated arterial carbon dioxide levels while awake (PaCO2 ≥ 45mmHg).~* Participants who have had surgery of the upper airway, nose, sinus, or middle ear within the previous 90 days.~* Participants with untreated, non-obstructive Sleep Apnea (OSA)/ Complex Sleep Apnea (CSA) sleep disorders, including but not limited to; insomnia, periodic limb movement syndrome, or restless legs syndrome (PLM Arousal Index \> 15).

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- BiPAP auto SV Advanced (Type: ACTIVE_COMPARATOR): BiPAP auto SV Advanced
- BiPAP auto SV 4 (Type: EXPERIMENTAL): Auto Servo Ventilation Device

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: CORAL XT - Open-label Extension Trial of the CORAL Trial

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Informed consent signed indicating that the participant understands the purpose of and procedures required for the trial and is willing to participate in the trial.~* Participants must be at least 18 years of age at the Enrollment Visit.~* Women of childbearing potential must have a negative pregnancy test at enrollment and must not be lactating at the Enrollment Visit.~* Participants must be willing to use medically acceptable and highly effective methods of birth control.~* Participants who have completed treatment in KF6005/07 and are still in need of around-the-clock pain analgesia with strong opioids.~Exclusion Criteria:~* The participant has a clinically significant disease or condition other than cancer which in the investigator's opinion may affect efficacy or safety assessments.~* Known to or suspected of not being able to comply with the protocol and the use of cebranopadol.~* Participants taking forbidden concomitant medications or not being able to follow the rules of use of concomitant treatment.~* History of torsade de pointes and/or presence of risk factors for torsade de pointes (e.g., heart failure, hypokalemia, bradycardia).~* Concurrent participation in another trial (except participation in KF6005/07) or planning to be enrolled in another clinical trial (i.e., administration of experimental treatment in another clinical trial) during the course of this trial, or previous participation in this trial.~* Employees of the sponsor, investigator, or trial site or family members of the employees, sponsor, or investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cebranopadol (Type: EXPERIMENTAL): Cebranopadol 200 µg to 1000 µg per taken taken once a day in the morning.~Allowed dose levels in the Maintenance Phase were 200, 400, 600, 800, or 1000 µg per day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in People Who Are Overweight or Living With Obesity (OASIS 1)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, age greater than or equal to 18 years at the time of signing informed consent~* Body mass index (BMI):~greater than or equal to 27.0 kg/m\^2 with the presence of at least one of the following weight-related complications (treated or untreated): hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease OR greater than or equal to 30.0 kg/m\^2~* History of at least one self-reported unsuccessful dietary effort to lose body weight~Exclusion Criteria:~* HbA1c greater than or equal to 6.5% (48 mmol/mol) as measured by the central laboratory at screening~* A self-reported change in body weight greater than 5 kg (11 lbs) within 90 days before screening irrespective of medical records

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Oral semaglutide (Type: EXPERIMENTAL): Participants will receive once daily semaglutide tables in a dose escalating manner for 68 weeks: 3 mg (week 1-4), 7 mg (week 5-8), 14 mg (week 9-12), 25 mg (week 13-16) and 50 mg (week 17-68)
- Oral semaglutide placebo (Type: PLACEBO_COMPARATOR): All participants are given once daily dose for 68 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Participant Responses to Educational Counseling About Different Combined Hormonal Contraceptive Choices (P06557)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Healthy women ≥ 18 years of age and ≤ 40 years of age who consult their physician for contraception and would consider a combined hormonal contraceptive method~* Women who are using the hormonal method for the first time or who have previously used and suspended it for at least 1 month~* Women on one combined pill who would consider switching to another combined pill (Women who attend their physician to stop one of the combined hormonal methods can not participate)~* Women who request a combined hormonal contraceptive method but for whom the physician considers another method more appropriate (e.g. contraindications for combined hormonal contraception) will be counseled about these methods but still complete the questionnaire~* Women who are not interested in becoming pregnant in the next 4 months~* Women who agree to complete a questionnaire and that the questionnaire data are reviewed and analyzed by staff participating in the project~Exclusion Criteria:~None

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- All Qualified Participants (Type: None): All healthy women who consulted their physician for information on contraceptive choices and were eligible for primary and secondary outcome measure analysis, based on the physician's assessment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: N-Acetyl Cysteine in Pathologic Skin Picking

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Men and women age 18-65;~2. Current diagnosis of pathologic skin picking as determined by criteria proposed by Arnold et al. (2001) for at least 6 months duration~Exclusion Criteria:~1. Unstable medical illness or clinically significant abnormalities on prestudy laboratory tests or physical examination;~2. History of seizures;~3. Myocardial infarction within 6 months;~4. Current pregnancy or lactation, or inadequate contraception in women of childbearing potential;~5. Need for medication other than NAC with possible psychotropic effects or unfavorable interactions with NAC;~6. Clinically significant suicidality (score or 3 or 4 on item 3 of the Hamilton Depression Rating Scale);~7. Lifetime history of DSM-IV bipolar disorder type I, dementia, or schizophrenia or any other DSM-IV psychotic disorder;~8. Current or recent (past 3 months) DSM-IV substance abuse or dependence;~9. Illegal substance use within 2 weeks of study initiation;~10. Initiation of pharmacotherapy, psychotherapy, or behavior therapy from a mental health professional within 3 months prior to study baseline for the treatment of pathologic skin picking;~11. Previous treatment with N-acetyl cysteine;~12. Treatment with investigational medication or depot neuroleptics within 3 months, with fluoxetine within 6 weeks, or with other psychotropics within 2 weeks prior to study baseline;~13. Asthma (given possible worsening of asthma due to NAC)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- N-Acetyl Cysteine (Type: ACTIVE_COMPARATOR): N-Acetyl Cysteine - 600mg tablets by mouth (dosing 1200mg - 3000mg qd)
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo taken daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete